Innate Pharma (IPHA) Non-Current Deffered Revenue (2017 - 2025)
Innate Pharma's (IPHA) quarterly Non-Current Deffered Revenue came in at $3.0 million in Q2 2025, down 93.41% YoY from $45.1 million in Q2 2024, and down 1.46% on a QoQ basis from $3.0 million in Q4 2024.
Innate Pharma (IPHA) Non-Current Deffered Revenue (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Non-Current Deffered Revenue data on file, last reported at $3.0 million in Q2 2025.
- Quarterly Non-Current Deffered Revenue fell 93.41% year-over-year to $3.0 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $3.0 million (down 93.41% YoY) and the FY2024 annual result came in at $3.0 million, down 39.24% from the prior year.
- Non-Current Deffered Revenue retreated to $3.0 million in Q2 2025, from $3.0 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $45.1 million in Q2 2024 to a low of $3.0 million in Q2 2025.
- A 5-year average of $15.8 million and a median of $8.1 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue slumped 99.84% — and 2024, when it jumped 593.64%.
- Tracing IPHA's Non-Current Deffered Revenue over 5 years: stood at $29.1 million in 2021, then tumbled by 72.2% to $8.1 million in 2022, then tumbled by 38.52% to $5.0 million in 2023, then sank by 39.24% to $3.0 million in 2024, then declined by 1.46% to $3.0 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $3.0 million (Q2 2025), $3.0 million (Q4 2024), and $45.1 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2.97 Mn |
| Dec 31, 2024 | 3.02 Mn |
| Jun 30, 2024 | 45.12 Mn |
| Dec 31, 2023 | 4.97 Mn |
| Jun 30, 2023 | 6.51 Mn |
| Dec 31, 2022 | 8.08 Mn |
| Jun 30, 2022 | 8.89 Mn |
| Dec 31, 2021 | 29.07 Mn |
| Jun 30, 2021 | 33.24 Mn |
| Dec 31, 2020 | 38.96 Mn |
| Jun 30, 2020 | 20.49 Bn |
| Dec 31, 2019 | 44.65 Mn |
| Dec 31, 2018 | 77.73 Mn |
| Dec 31, 2017 | 102.44 Mn |